Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 13, 2018 - Issue
Submit an article Journal homepage
100
Views
24
CrossRef citations to date
0
Altmetric
Original Research

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids

Salman H Siddiqui1 University of Leicester, Leicester, UK, [email protected];2 National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK, [email protected]Correspondence[email protected]
,
Ian D Pavord3 Respiratory Theme, National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK;4 Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK
,
Neil C Barnes5 Glaxo Smith Kline, Brentford, London, UK;6 Barts and The London School of Medicine and Dentistry, London, UK
,
Alessandro Guasconi7 Chiesi Farmaceutici SpA, Parma, Italy
,
Sally Lettis8 GSK, Uxbridge, London, UK
,
Steven Pascoe9 GSK, King of Prussia, PA, USA
&
Stefano Petruzzelli7 Chiesi Farmaceutici SpA, Parma, Italy
 show all
Pages 3669-3676 | Published online: 06 Nov 2018

References

  • PriceDRigazioAPostmaDBlood eosinophilia and the number of exacerbations in COPD patients [abstract]Eur Respir J201444Suppl 584416
  • Vedel-KroghSNielsenSFLangePVestboJNordestgaardBGBlood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population StudyAm J Respir Crit Care Med2016193996597426641631
  • PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPDThorax201671211812526585525
  • BarnesNCSharmaRLettisSCalverleyPMBlood eosinophils as a marker of response to inhaled corticosteroids in COPDEur Respir J20164751374138226917606
  • BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
  • WatzHTetzlaffKWoutersEFBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
  • PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
  • SiddiquiSHGuasconiAVestboJBlood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2015192452352526051430
  • DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
  • WedzichaJASinghDVestboJFORWARD InvestigatorsExtrafine beclomethasone/formoterol in severe COPD patients with history of exacerbationsRespir Med201410881153116224953015
  • WedzichaJABanerjiDChapmanKRFLAME InvestigatorsIndacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDN Engl J Med2016374232222223427181606

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.